Biotech Values

[DewDiligence]

AMRN—You asked the same question five months ago in #msg-84852031, and I replied that AMRN (then) was fairly valued to slightly overvalued at an enterprise value of $1.2B.

Now, the EV is 25% lower (~$900M), but AMRN’s prospects have deteriorated to some degree because the Vascepa launch is slower than expected and no partnership deal has been inked.

All told, I would say that AMRN is still somewhere between fairly valued to slightly overvalued.